Strategic partnerships Capitalize on high-profile funding rounds and FDA Fast Track designation to pursue partnerships with larger biopharma or contract development organizations for ADP101 manufacturing, distribution, and later-stage trials.

Clinical momentum Leverage the ongoing Phase 1/2 Harmony study results and safety data to pursue investigator-initiated studies, payer discussions, and regional licensing deals to accelerate market access for multi-allergen oral immunotherapy.

Regulatory leverage Target opportunities with regulatory affairs teams to align on Fast Track implications, potential accelerated pathways, and strategic co-development agreements that could shorten time-to-market for ADP101.

Market positioning Position ADP101 as a leading multi-allergen OIT with unmet needs in food allergy, approaching pediatric and adult specialty clinics, allergists, and hospital systems for early access programs and reimbursement conversations.

Digital and operations Offer streamlined clinical and commercial enablement through existing tech stack (DocuSign, Webflow, Smartsheet, Google Workspace) to potential partners, emphasizing efficient contracting, data sharing, and joint market access playbooks.